Suzhou Basecare Medical (HKSE:02170) ROCE %: -15.05% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02170 Suzhou Basecare Medical Corp Ltd HKSE:02170
70 GF Score
Price HK$1.40
GF Value HK$2.94
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Suzhou Basecare Medical ROCE %?

Suzhou Basecare Medical HKSE:02170 70 ROCE % is -15.05% as of Dec. 2025. GuruFocus rates HKSE:02170 with a GF Score™ of 70/100 and a GF Value™ of HK$2.94 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Suzhou Basecare Medical's annualized ROCE % for the quarter that ended in Dec. 2025 was -15.05%.

Suzhou Basecare Medical  (HKSE:02170) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Suzhou Basecare Medical ROCE % Related Terms

Suzhou Basecare Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Suzhou Basecare Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Basecare Medical ROCE % Chart

Suzhou Basecare Medical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -12.36 -7.06 -11.38 -14.35 -15.97

Suzhou Basecare Medical Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.52 -14.13 -14.68 -16.50 -15.05
HKSE:02170
70GF Score
Suzhou Basecare Medical Corp Ltd HKSE:02170
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Basecare Medical ROCE % Calculation

Suzhou Basecare Medical's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-236.497/( ( (1782.245 - 207.859) + (1597.921 - 210.22) )/ 2 )
=-236.497/( (1574.386+1387.701)/ 2 )
=-236.497/1481.0435
=-15.97 %

Suzhou Basecare Medical's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-217.038/( ( (1712.851 - 216.958) + (1597.921 - 210.22) )/ 2 )
=-217.038/( ( 1495.893 + 1387.701 )/ 2 )
=-217.038/1441.797
=-15.05 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -15.05% mean?
Suzhou Basecare Medical (HKSE:02170) has a ROCE % of -15.05% as of Dec. 2025.
Is Suzhou Basecare Medical's ROCE % too high?
Suzhou Basecare Medical's current ROCE % is -15.05%. Overall, Suzhou Basecare Medical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Suzhou Basecare Medical's ROCE % compare to ABT and SYK?
Suzhou Basecare Medical's ROCE % of -15.05% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.22, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Basecare Medical's current ROCE % is -15.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Basecare Medical stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Basecare Medical (HKSE:02170) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.94, compared to a current price of HK$1.40 — trading 52.4% below its estimated fair value. The current ROCE % is -15.05%. Suzhou Basecare Medical's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Suzhou Basecare Medical (HKSE:02170), the current ROCE % is -15.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Basecare Medical (HKSE:02170) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Basecare Medical stock appears to be undervalued. The current stock price of HK$1.40 is trading 52.4% below its estimated GF Value™ of HK$2.94. GuruFocus considers Suzhou Basecare Medical to be Possible Value Trap.

Key valuation signals for HKSE:02170:

  • ROCE %: -15.05%
  • GF Value™: HK$2.94 vs. price of HK$1.40 (52.4% below fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Suzhou Basecare Medical Business Description

Address No. 77 Jingu Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN
Suzhou Basecare Medical Corp Ltd is a medical device company based in China, operating in the field of assisted reproduction. It is engaged in the research, development, and provision of medical products and related software in the field of reproductive health, to enable more families to have children. The Group's product portfolio comprises Gems Sperm Wash Gradient Set, Gems Fertilisation Medium, Gavi Instrument, Geri Incubator, Cryostorage System, PGT-A kit, Self sperm testing device, Sperm quality analyser, Genie sequencer, and others. It generates maximum revenue from the sale of testing kits. The Group's reportable segments are: the PRC, which derives maximum revenue, and Australia. Geographically, it operates in the PRC, Europe, Asia (excluding the PRC), and other regions.
70GF Score

Get the complete analysis for HKSE:02170

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.40
Price
HK$2.94
GF Value